The estimated Net Worth of Andrew Craig Miller is at least $31.7 Миллион dollars as of 18 April 2023. Andrew Miller owns over 45,000 units of Karuna Therapeutics Inc stock worth over $8,047,852 and over the last 5 years he sold KRTX stock worth over $22,236,225. In addition, he makes $1,447,240 as Chief Operating Officer at Karuna Therapeutics Inc.
Sign up
Andrew Miller KRTX stock SEC Form 4 insiders trading
Andrew has made over 24 trades of the Karuna Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 45,000 units of KRTX stock worth $9,006,750 on 18 April 2023.
The largest trade he's ever made was exercising 58,000 units of Karuna Therapeutics Inc stock on 12 June 2020 worth over $309,720. On average, Andrew trades about 13,912 units every 37 days since 2020. As of 18 April 2023 he still owns at least 24,400 units of Karuna Therapeutics Inc stock.
You can see the complete history of Andrew Miller stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Miller biography
Dr. Andrew Craig Miller Ph.D. serves as Chief Operating Officer of the Company. Dr. Miller has served as our Chief Operating Officer since August 2018 and served as a member of our board of directors from April 2012 to March 2019. Dr. Miller was our founder and prior to serving as our Chief Operating Officer, he was our President and Chief Executive Officer from July 2016 to August 2018. From August 2008 to July 2016, Dr. Miller held several positions at PureTech Health plc, last serving as a Vice President, Venture Partner at PureTech Health plc, and in such capacity served as Chief Operating Officer of Tal Medical and acting Chief Operating Officer of Entrega, Inc. He is currently a member of the board of directors of Entrega, Inc. Dr. Miller received a B.S. in Chemical Engineering from the University of Illinois with highest honors and completed his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology.
What is the salary of Andrew Miller?
As the Chief Operating Officer of Karuna Therapeutics Inc, the total compensation of Andrew Miller at Karuna Therapeutics Inc is $1,447,240. There are 1 executives at Karuna Therapeutics Inc getting paid more, with Steven Paul having the highest compensation of $10,050,700.
How old is Andrew Miller?
Andrew Miller is 38, he's been the Chief Operating Officer of Karuna Therapeutics Inc since 2018. There are 15 older and no younger executives at Karuna Therapeutics Inc. The oldest executive at Karuna Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the CEO, Pres & Chairman.
What's Andrew Miller's mailing address?
Andrew's mailing address filed with the SEC is C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON, MA, 02110.
Insiders trading at Karuna Therapeutics Inc
Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over $496,938,545 worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth $53,814,390 . The most active insiders traders include Health Llc Pure Tech, James Healy и Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $18,341,187. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth $636,600.
What does Karuna Therapeutics Inc do?
we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip
What does Karuna Therapeutics Inc's logo look like?
Complete history of Andrew Miller stock trades at Karuna Therapeutics Inc
Karuna Therapeutics Inc executives and stock owners
Karuna Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Steven Paul,
Chairman of the Board, President, Chief Executive Officer -
Andrew Miller,
Chief Operating Officer -
Edmund Harrigan,
Independent Director -
Troy Ignelzi,
Chief Financial Officer -
Dr. Steven M. Paul M.D.,
CEO, Pres & Chairman -
Dr. Andrew Craig Miller,
Co-Founder & COO -
Dr. Stephen K. Brannan,
Chief Medical Officer -
Dr. Troy A. Ignelzi,
CFO & Sec. -
Stephen Brannan,
Chief Medical Officer -
Atul Pande,
Independent Director -
James Healy,
Independent Director -
Jeffrey Jonas,
Director -
Heather Preston,
Independent Director -
Robert Nelsen,
Independent Director -
Christopher Coughlin,
Independent Director -
Laurie Olson,
Director -
Giorgio Attardo,
Vice President, CMC and Preclinical Development -
Dr. Ronald N. Marcus M.D.,
Sr. VP of Medical -
Charmaine Lykins,
Chief Commercial Officer -
Dr. James E. Audia Ph.D.,
Head of Medicinal Chemistry & Sr. Adviser -
Dr. Alan Breier,
Chair of Scientific Advisory Board & Chief Clinical Advisor -
Stephanie Moore,
VP of HR -
Sharon Sawchak R.N.,
VP of Clinical Operations & Compliance -
Mia Kelley J.D.,
VP of Legal Affairs -
Jason Parker Brown,
VP of Corp. Fin. -
Venture Partners Ix, Llcarc...,
-
William Meury,
President and CEO -
Bharat M Chowrira,
Director -
Venture Partners Ix, Llcarc...,
-
Charmaine Lykins,
Chief Commercial Officer -
Health Llc Pure Tech,
-
David E. Wheadon,
-
Denice Torres,
-
William P Jr Kane,
Chief Commercial Officer -
Jason Parker Brown,
Chief Financial Officer